1
|
Rodan GA and Martin TJ: Therapeutic
approaches to bone diseases. Science. 289:1508–1514. 2000.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Riggs BL and Parfitt AM: Drugs used to
treat osteoporosis: The critical need for a uniform nomenclature
based on their action on bone remodeling. J Bone Miner Res.
20:177–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
3
|
Augustine M and Horwitz MJ: Parathyroid
hormone and parathyroid hormone-related protein analogs as
therapies for osteoporosis. Curr Osteoporos Rep. 11:400–406. 2013.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Skjødt MK, Frost M and Abrahamsen B: Side
effects of drugs for osteoporosis and metastatic bone disease. Br J
Clin Pharmacol. 2018.(Epub ahead of print). doi: 10.1111/bcp.13759.
View Article : Google Scholar
|
5
|
Long F: Building strong bones: Molecular
regulation of the osteoblast lineage. Nat Rev Mol Cell Biol.
13:27–38. 2011. View
Article : Google Scholar : PubMed/NCBI
|
6
|
Huang W, Yang S, Shao J and Li YP:
Signaling and transcriptional regulation in osteoblast commitment
and differentiation. Front Biosci. 12:3068–3092. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rawadi G and Roman-Roman S: Wnt signaling
pathway: A new target for the treatment of osteoporosis. Expert
Opin Ther Targets. 9:1063–1077. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Kamiya N: The role of BMPs in bone
anabolism and their potential targets SOST and DKK1. Curr Mol
Pharmacol. 5:153–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Pinzone JJ, Hall BM, Thudi NK, Vonau M,
Qiang YW, Rosol TJ and Shaughnessy JD Jr: The role of Dickkopf-1 in
bone development, homeostasis, and disease. Blood. 113:517–525.
2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Seo BK, Ryu HK, Park YC, Huh JE and Baek
YH: Dual effect of WIN-34B on osteogenesis and osteoclastogenesis
in cytokine-induced mesenchymal stem cells and bone marrow cells. J
Ethnopharmacol. 193:227–236. 2016. View Article : Google Scholar : PubMed/NCBI
|
11
|
Li Y, Cai W, Weng X, Li Q, Wang Y, Chen Y,
Zhang W, Yang Q, Guo Y, Zhu X, et al: Lonicerae Japonicae flos and
lonicerae flos: A systematic pharmacology review. Evid Based
Complement Alternat Med. 2015:9050632015.PubMed/NCBI
|
12
|
Xu JR, Li GF, Wang JY, Zhou JR and Han J:
Gout prophylactic constituents from the flower buds of Lonicera
japonica. Phytochem Lett. 15:98–102. 2016. View Article : Google Scholar
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Marie PJ and Kassem M: Osteoblasts in
osteoporosis: Past, emerging, and future anabolic targets. Eur J
Endocrinol. 165:1–10. 2011. View Article : Google Scholar : PubMed/NCBI
|
15
|
Otsuka E, Yamaguchi A, Hirose S and
Hagiwara H: Characterization of osteoblastic differentiation of
stromal cell line ST2 that is induced by ascorbic acid. Am J
Physiol. 277:C132–C138. 1999. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yamaguchi A, Ishizuya T, Kintou N, Wada Y,
Katagiri T, Wozney JM, Rosen V and Yoshiki S: Effects of BMP-2,
BMP-4, and BMP-6 on osteoblastic differentiation of bone
marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem
Biophys Res Commun. 220:366–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kim MB, Song Y and Hwang JK: Kirenol
stimulates osteoblast differentiation through activation of the BMP
and Wnt/β-catenin signaling pathways in MC3T3-E1 cells.
Fitoterapia. 98:59–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Aubin JE: Bone stem cells. J Cell Biochem
Suppl. 30-31:73–82. 1998. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wan M and Cao X: BMP signaling in skeletal
development. Biochem Biophys Res Commun. 328:651–657. 2005.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhao M, Harris SE, Horn D, Geng Z,
Nishimura R, Mundy GR and Chen D: Bone morphogenetic protein
receptor signaling is necessary for normal murine postnatal bone
formation. J Cell Biol. 157:1049–1060. 2002. View Article : Google Scholar : PubMed/NCBI
|
21
|
Jia TL, Wang HZ, Xie LP, Wang XY and Zhang
RQ: Daidzein enhances osteoblast growth that may be mediated by
increased bone morphogenetic protein (BMP) production. Biochem
Pharmacol. 65:709–715. 2003. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lo YC, Chang YH, Wei BL, Huang YL and
Chiou WF: Betulinic acid stimulates the differentiation and
mineralization of osteoblastic MC3T3-E1 cells: Involvement of
BMP/Runx2 and beta-catenin signals. J Agric Food Chem.
58:6643–6649. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Krishnan V, Bryant HU and Macdougald OA:
Regulation of bone mass by Wnt signaling. J Clin Invest.
116:1202–1209. 2006. View
Article : Google Scholar : PubMed/NCBI
|
24
|
MacDonald BT and He X: Frizzled and LRP5/6
receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect
Biol. 4(pii): a0078802012.PubMed/NCBI
|
25
|
Kikuchi A: Regulation of beta-catenin
signaling in the Wnt pathway. Biochem Biophys Res Commun.
268:243–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
26
|
Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR,
Kyung HM, Sung JH, Wozney JM, Kim HJ and Ryoo HM: BMP-2-induced
Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the
BMP-2-induced osteoblast differentiation by suppression of Dlx5
expression. J Biol Chem. 278:34387–34394. 2003. View Article : Google Scholar : PubMed/NCBI
|